2024
Cerebrovascular Events in Patients Undergoing Transcatheter Aortic Valve Replacement: A Review
Patel K, Rathod K, Lansky A, Prendergast B, Kharbanda R, Mathur A, Perry R, Baumbach A. Cerebrovascular Events in Patients Undergoing Transcatheter Aortic Valve Replacement: A Review. Stroke 2024, 55: 2754-2764. PMID: 39371005, DOI: 10.1161/strokeaha.124.047149.Peer-Reviewed Original ResearchTranscatheter aortic valve replacementAortic valve replacementCerebrovascular eventsValve replacementAtrial fibrillationLow operative risk patientsAdvent of transcatheter aortic valve replacementNew-onset atrial fibrillationComplication of transcatheter aortic valve replacementIncreased risk of bleedingHigher risk of cerebrovascular eventsAssociated with significant mortalityTranscatheter aortic valve replacement procedureRisk of cerebrovascular eventsOperative risk patientsResults of embolizationRisk of bleedingRisk of thromboembolismHypoattenuated leaflet thickeningImprove risk stratificationCerebral lesion volumeAssociated with cerebrovascular eventsTherapy to patientsOverall stroke rateSeverity of comorbidities
2023
Protrieve sheath utilization for capturing supra-filter thrombus during a retrieval of thrombosed and embedded IVC filter
Shewarega A, Powell T, Silin D. Protrieve sheath utilization for capturing supra-filter thrombus during a retrieval of thrombosed and embedded IVC filter. CVIR Endovascular 2023, 6: 52. PMID: 37882904, PMCID: PMC10602975, DOI: 10.1186/s42155-023-00397-4.Peer-Reviewed Original ResearchIVC filtersPulmonary embolismDeep vein thrombosisCase presentationA 54-year-old womanBackgroundInferior vena cavaEmbedded IVC filtersIndwelling IVC filterHigher transfusion requirementsRecurrent pulmonary embolismLower extremity swellingPreventing pulmonary embolismIron deficiency anemiaRisk of thromboembolismIn situ thrombosisRisk of embolismComplex medical historyIVC thrombosisTransfusion requirementsTemporary filterAnticoagulant therapyExtremity swellingVena cavaVein thrombosisGastrointestinal bleedingCase reportCerebral Embolic Risk in Coronary and Structural Heart Interventions: Clinical Evidence
Tirziu D, Huang H, Parise H, Pietras C, Moses J, Messé S, Lansky A. Cerebral Embolic Risk in Coronary and Structural Heart Interventions: Clinical Evidence. Journal Of The Society For Cardiovascular Angiography & Interventions 2023, 2: 100631. PMID: 39130705, PMCID: PMC11307836, DOI: 10.1016/j.jscai.2023.100631.Peer-Reviewed Original ResearchStructural heart interventionsHeart interventionsCardiac proceduresBrain injuryLong-term neurocognitive sequelaeTranscatheter aortic valve replacement (TAVR) proceduresAortic valve replacement proceduresCerebral embolic riskIatrogenic brain injuryIschemic brain injuryRisk of thromboembolismCoronary artery diseaseEmbolic protection devicesNumber of patientsValve replacement proceduresPercutaneous transcatheter interventionsLikelihood of disabilitySymptomatic strokeCerebral embolismCerebral embolizationEmbolic riskAcute strokeNeurologic injuryArtery diseaseIschemic infarction
2022
Residual stroke risk despite oral anticoagulation in patients with atrial fibrillation
Carlisle M, Shrader P, Fudim M, Pieper K, Blanco R, Fonarow G, Naccarelli G, Gersh B, Reiffel J, Kowey P, Steinberg B, Freeman J, Ezekowitz M, Singer D, Allen L, Chan P, Pokorney S, Peterson E, Piccini J, Patients and Investigators O. Residual stroke risk despite oral anticoagulation in patients with atrial fibrillation. Heart Rhythm O2 2022, 3: 621-628. PMID: 36589908, PMCID: PMC9795305, DOI: 10.1016/j.hroo.2022.09.018.Peer-Reviewed Original ResearchTransient ischemic attackPermanent atrial fibrillationOral anticoagulationAtrial fibrillationVASc scoreIschemic attackThromboembolic eventsFemale sexPrevious stroke/transient ischemic attackStroke/transient ischemic attackTransient ischemic attack eventsCox proportional hazard modelingResidual riskResidual stroke riskBetter Informed TreatmentRisk of thromboembolismProportional hazard modelingSystemic embolismPrevious strokeStroke riskOutcomes RegistryMean ageRisk markersOutcome eventsThromboembolism
2021
Leaks after Left Atrial Appendage Closure: Ignored or Neglected?
Jang S, Wong S, Mosadegh B. Leaks after Left Atrial Appendage Closure: Ignored or Neglected? Cardiology 2021, 146: 384-391. PMID: 33735867, DOI: 10.1159/000513901.Peer-Reviewed Original ResearchConceptsPeri-device leakAtrial appendage closureLAA closureThromboembolic eventsAppendage closureLong-term oral anticoagulationLeft atrial appendage closureLarger long-term studiesEpicardial LAA closureChronic atrial fibrillationRisk of thromboembolismHigh-velocity blood flowIncomplete LAA closureLong-term safetySmall study populationLAA closure procedureAtrial ostiumOral anticoagulationStroke preventionPercutaneous closureAtrial fibrillationResidual leakIncrease of riskClinical significanceStudy population
2017
Neuraxial Anesthesia in Obstetric Patients Receiving Thromboprophylaxis With Unfractionated or Low-Molecular-Weight Heparin
Leffert LR, Dubois HM, Butwick AJ, Carvalho B, Houle TT, Landau R. Neuraxial Anesthesia in Obstetric Patients Receiving Thromboprophylaxis With Unfractionated or Low-Molecular-Weight Heparin. Anesthesia & Analgesia 2017, 125: 223-231. PMID: 28628578, DOI: 10.1213/ane.0000000000002173.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAnesthesia, ConductionAnesthesia, ObstetricalAnesthesiologyAnestheticsAnticoagulantsCesarean SectionDelivery, ObstetricFemaleHematoma, Epidural, SpinalHeparinHeparin, Low-Molecular-WeightHumansMiddle AgedNerve BlockPregnancyPregnancy Complications, CardiovascularThrombosisYoung AdultConceptsSpinal epidural hematomaCases of SEHNeuraxial anesthesiaObstetric patientsVenous thromboembolismWeight heparinAnesthesia Closed Claims Project databaseSystematic reviewPractice changePostpartum venous thromboembolismVaginal delivery hospitalizationsWeight heparin doseRisk of thromboembolismLarge-scale registriesMajority of womenEnglish-language studiesAnticoagulated womenDelivery hospitalizationsPharmacological thromboprophylaxisAnticoagulant doseCesarean deliveryEpidural hematomaHeparin doseVaginal deliveryGeneral anesthesia
2014
The Risks of Thromboembolism Vs. Recurrent Gastrointestinal Bleeding after Interruption of Systemic Anticoagulation in Hospitalized Inpatients With Gastrointestinal Bleeding: A Prospective Study
Sengupta N, Feuerstein J, Patwardhan V, Tapper E, Ketwaroo G, Thaker A, Leffler D. The Risks of Thromboembolism Vs. Recurrent Gastrointestinal Bleeding after Interruption of Systemic Anticoagulation in Hospitalized Inpatients With Gastrointestinal Bleeding: A Prospective Study. The American Journal Of Gastroenterology 2014, 110: 328. PMID: 25512338, DOI: 10.1038/ajg.2014.398.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAnticoagulantsBenzimidazolesbeta-AlanineCohort StudiesDabigatranEnoxaparinFemaleGastrointestinal HemorrhageHeparinHumansIschemic Attack, TransientLongitudinal StudiesMaleMiddle AgedMorpholinesPatient ReadmissionProspective StudiesPulmonary EmbolismPyrazolesPyridonesRecurrenceRivaroxabanStrokeThiophenesThromboembolismVenous ThrombosisWarfarinWithholding TreatmentConceptsRecurrent gastrointestinal bleedingGastrointestinal bleedingSystemic anticoagulationAnticoagulation continuationThromboembolic eventsThrombotic eventsEtiology of GIBProspective observational cohort studyIntensive care unit careHospital transfusion requirementsMajor thrombotic episodesRisk of continuationObservational cohort studyRisk of thromboembolismCox proportional hazardsTransfusion requirementsCohort studyHospital dischargeUnit careConsecutive patientsHospital readmissionThrombotic episodesProspective studyHospitalized inpatientsFollowing outcomesManagement of Hypertrophic Cardiomyopathy
Enriquez AD, Goldman ME. Management of Hypertrophic Cardiomyopathy. Annals Of Global Health 2014, 80: 35-45. PMID: 24751563, DOI: 10.1016/j.aogh.2013.12.004.Peer-Reviewed Original ResearchConceptsSudden cardiac deathHypertrophic cardiomyopathyHeart failureAtrial fibrillationHCM patientsManagement of HCMCommon genetic cardiovascular diseaseUnexplained myocardial hypertrophyAlcohol septal ablationOutflow tract obstructionRhythm control strategyPathophysiology of HCMRisk of thromboembolismMajority of patientsGeneral adult populationGenetic cardiovascular diseaseAutosomal dominant diseaseFamily membersSurgical myectomyRefractory symptomsRestrictive physiologySeptal ablationTract obstructionYounger patientsCardiac death
2012
Risk of Venous Thromboembolism in Patients With Cancer Treated With Cisplatin: A Systematic Review and Meta-Analysis
Seng S, Liu Z, Chiu S, Proverbs-Singh T, Sonpavde G, Choueiri T, Tsao C, Yu M, Hahn N, Oh W, Galsky M. Risk of Venous Thromboembolism in Patients With Cancer Treated With Cisplatin: A Systematic Review and Meta-Analysis. Journal Of Clinical Oncology 2012, 30: 4416-4426. PMID: 23150697, DOI: 10.1200/jco.2012.42.4358.Peer-Reviewed Original ResearchConceptsRisk of venous thromboembolic eventsCisplatin-based chemotherapyVenous thromboembolic eventsNon-cisplatin-based chemotherapySolid tumorsRandomized Controlled TrialsIncreased risk of VTENon-cisplatin-based regimensIncreased riskPatients treated with cisplatin-based chemotherapyIncidence of venous thromboembolic eventsIncreased risk of thromboembolismMeta-analysis of randomized controlled trialsRisk of venous thromboembolismControlled TrialsAdvanced solid tumorsMeta-analysisRisk of thromboembolismExploratory subgroup analysisRandom-effects modelCisplatin-basedCisplatin doseIII trialsThromboembolic eventsVenous thromboembolismRisk of venous thromboembolism in cancer patients treated with cisplatin: A systematic review and meta-analysis.
Seng S, Liu Z, Chiu S, Proverbs-Singh T, Sonpavde G, Choueiri T, Tsao C, Yu M, Hahn N, Oh W, Galsky M. Risk of venous thromboembolism in cancer patients treated with cisplatin: A systematic review and meta-analysis. Journal Of Clinical Oncology 2012, 30: e21016-e21016. DOI: 10.1200/jco.2012.30.15_suppl.e21016.Peer-Reviewed Original ResearchRisk of venous thromboembolic eventsCisplatin-based chemotherapyVenous thromboembolic eventsPatients treated with cisplatin-based chemotherapyRandomized Controlled TrialsAdvanced solid tumorsThromboembolic eventsSolid tumorsCisplatin doseMeta-analysisIncreased risk of VTESubgroup analysisConfidence intervalsNon-cisplatin-based chemotherapyIncreased riskIncidence of venous thromboembolic eventsCancer patients treated with cisplatinPatients treated with cisplatinIncreased risk of thromboembolismMeta-analysis of randomized controlled trialsRisk of venous thromboembolismNon-cisplatin chemotherapyRisk of thromboembolismTrial of patientsHigher relative risk
2009
Preterm delivery and risk of subsequent cardiovascular morbidity and type‐II diabetes in the mother
Lykke J, Paidas M, Damm P, Triche E, Kuczynski E, Langhoff‐Roos J. Preterm delivery and risk of subsequent cardiovascular morbidity and type‐II diabetes in the mother. BJOG An International Journal Of Obstetrics & Gynaecology 2009, 117: 274-281. PMID: 20015308, DOI: 10.1111/j.1471-0528.2009.02448.x.Peer-Reviewed Original ResearchConceptsRisk of thromboembolismType II diabetesPreterm deliveryCardiovascular morbiditySingleton deliveriesRegistry-based retrospective cohort studyCox proportional hazards modelFirst singleton deliveryHypertensive pregnancy disordersMaternal cardiovascular morbiditySecond singleton deliverySpecific cardiovascular eventsSubsequent cardiovascular morbidityRetrospective cohort studyIschemic heart diseaseWeeks of gestationYear of deliveryProportional hazards modelFetal growth deviationsMaternal hypertensionAdjusted riskCardiovascular eventsPlacental abruptionPregnancy complicationsCohort study
2007
Phase II Study of Low Dose and High Dose Conjugated Estrogen for Androgen Independent Prostate Cancer
Pomerantz M, Manola J, Taplin M, Bubley G, Inman M, Lowell J, Beard C, Kantoff P, Oh W. Phase II Study of Low Dose and High Dose Conjugated Estrogen for Androgen Independent Prostate Cancer. Journal Of Urology 2007, 177: 2146-2150. PMID: 17509304, DOI: 10.1016/j.juro.2007.01.119.Peer-Reviewed Original ResearchConceptsAndrogen-independent prostate cancerIndependent prostate cancerProstate specific antigenProstate cancerSpecific antigenDose armProgressive androgen-independent prostate cancerAdministered to most patientsStudy of low doseAndrogen-independent diseaseHigh dose armLow dose armProphylactic breast irradiationPhase II studyMonths of treatmentDehydroepiandrosterone sulfate levelsRisk of thromboembolismWarfarin 1 mgBreast irradiationThromboembolic eventsThromboembolic complicationsTherapeutic optionsConjugated estrogensMost patientsPremarin
2002
The Evolving Role of Estrogen Therapy in Prostate Cancer
Oh W. The Evolving Role of Estrogen Therapy in Prostate Cancer. Clinical Genitourinary Cancer 2002, 1: 81-89. PMID: 15046698, DOI: 10.3816/cgc.2002.n.009.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAgedAndrogen AntagonistsDiethylstilbestrolDose-Response Relationship, DrugDrug Administration ScheduleDrug Resistance, NeoplasmEstrogensFollow-Up StudiesHumansMaleMiddle AgedNeoplasm StagingProstate-Specific AntigenProstatic NeoplasmsRandomized Controlled Trials as TopicRisk AssessmentTreatment OutcomeConceptsLuteinizing hormone-releasing hormoneEstrogen therapyProstate cancerAndrogen-independent prostate cancer patientsHepatic first-pass metabolismNormal prostate developmentOral estrogen therapyToxicity of diethylstilbestrolNormal prostate epitheliumParenteral route of administrationMetastatic prostate cancerPhase II trialProstate-specific antigenProstate cancer patientsSafety of EstrogensRisk of thromboembolismHormone-releasing hormoneFirst-pass metabolismPrimary medical treatmentActivity of diethylstilbestrolRoute of administrationProstate developmentProstate epitheliumDevelopment of cancerLHRH agonist
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply